Trinity Biotech Plc Stock Analysis
TRIB Stock | USD 0.66 0.05 6.42% |
Trinity Biotech plc is undervalued with Real Value of 2.28 and Target Price of 7.0. The main objective of Trinity Biotech stock analysis is to determine its intrinsic value, which is an estimate of what Trinity Biotech plc is worth, separate from its market price. There are two main types of Trinity Biotech's stock analysis: fundamental analysis and technical analysis.
The Trinity Biotech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Trinity Biotech's ongoing operational relationships across important fundamental and technical indicators.
Trinity |
Trinity Stock Analysis Notes
About 12.0% of the company outstanding shares are owned by corporate insiders. The company has Price/Earnings To Growth (PEG) ratio of 1.3. Trinity Biotech plc recorded a loss per share of 2.25. The entity last dividend was issued on the 5th of June 2015. The firm had 1:5 split on the 23rd of February 2024. Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market in the Americas, Africa, Asia, and Europe. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland. Trinity Bio operates under Pharmaceuticals And Biosciences classification in the United States and is traded on NASDAQ Exchange. It employs 477 people. To find out more about Trinity Biotech plc contact Aris Kekedjian at 353 1 276 9800 or learn more at https://www.trinitybiotech.com.Trinity Biotech Quarterly Total Revenue |
|
Trinity Biotech plc Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Trinity Biotech's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Trinity Biotech plc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Trinity Biotech plc had very high historical volatility over the last 90 days | |
Trinity Biotech plc has some characteristics of a very speculative penny stock | |
Trinity Biotech plc has high likelihood to experience some financial distress in the next 2 years | |
The company reported the previous year's revenue of 56.83 M. Net Loss for the year was (24.02 M) with profit before overhead, payroll, taxes, and interest of 21.13 M. | |
Trinity Biotech plc currently holds about 10.01 M in cash with (11.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
Roughly 12.0% of the company outstanding shares are owned by corporate insiders | |
Latest headline from finance.yahoo.com: Adsposure and Trinity Metro Expand Partnership with 75 New Bus Shelters |
Trinity Biotech plc Upcoming and Recent Events
Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Trinity Biotech previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
28th of March 2024 Upcoming Quarterly Report | View | |
4th of July 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
28th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Trinity Largest EPS Surprises
Earnings surprises can significantly impact Trinity Biotech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2018-10-23 | 2018-09-30 | 0.06 | 0.05 | -0.01 | 16 | ||
2018-07-19 | 2018-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2018-03-07 | 2017-12-31 | 0.07 | 0.08 | 0.01 | 14 |
Trinity Stock Institutional Investors
Shares | Integrys Wealth Advisors Llc | 2024-12-31 | 10 K | Hartland & Co | 2024-12-31 | 10 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 2.2 K | Rhumbline Advisers | 2024-12-31 | 1.8 K | Simplex Trading, Llc | 2024-12-31 | 1.4 K | Jones Financial Companies Lllp | 2024-12-31 | 468 | Bank Of America Corp | 2024-12-31 | 240 | Atlantic Trust Group, Llc | 2024-12-31 | 222 | Atwood & Palmer Inc | 2024-12-31 | 20.0 | Perceptive Advisors Llc | 2024-12-31 | 1.8 M | Hunter Associates Inc. | 2024-12-31 | 378.6 K |
Trinity Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 19.48 M.Trinity Profitablity
The company has Profit Margin (PM) of (0.34) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.15) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.15.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.50) | (0.48) | |
Return On Capital Employed | (0.55) | (0.52) | |
Return On Assets | (0.36) | (0.35) | |
Return On Equity | 0.90 | 0.95 |
Management Efficiency
Trinity Biotech plc has return on total asset (ROA) of (0.0819) % which means that it has lost $0.0819 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (19.1345) %, meaning that it created substantial loss on money invested by shareholders. Trinity Biotech's management efficiency ratios could be used to measure how well Trinity Biotech manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 0.95, whereas Return On Tangible Assets are projected to grow to (0.48). At present, Trinity Biotech's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 69.5 M, whereas Total Assets are forecasted to decline to about 64.9 M.Last Reported | Projected for Next Year | ||
Book Value Per Share | (0.14) | (0.13) | |
Tangible Book Value Per Share | (0.30) | (0.29) | |
Enterprise Value Over EBITDA | (14.67) | (15.41) | |
Price Book Value Ratio | (0.79) | (0.75) | |
Enterprise Value Multiple | (3.00) | (3.14) | |
Price Fair Value | (0.79) | (0.75) | |
Enterprise Value | 5.5 B | 3.9 B |
The operational strategies employed by Trinity Biotech management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Technical Drivers
As of the 24th of March, Trinity Biotech has the Risk Adjusted Performance of 0.0192, coefficient of variation of 8847.26, and Semi Deviation of 6.28. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Trinity Biotech plc, as well as the relationship between them.Trinity Biotech plc Price Movement Analysis
java.lang.NullPointerException: Cannot invoke "java.lang.Number.intValue()" because the return value of "sun.invoke.util.ValueConversions.primitiveConversion(sun.invoke.util.Wrapper, Object, boolean)" is null. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Trinity Biotech middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Trinity Biotech plc. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Trinity Biotech Outstanding Bonds
Trinity Biotech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Trinity Biotech plc uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Trinity bonds can be classified according to their maturity, which is the date when Trinity Biotech plc has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Dana 575 percent Corp BondUS235822AB96 | View | |
TRINITY ACQUISITION PLC Corp BondUS89641UAC53 | View | |
Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
Valero Energy Partners Corp BondUS91914JAA07 | View | |
AerCap Global Aviation Corp BondUS00773HAA59 | View |
Trinity Biotech Predictive Daily Indicators
Trinity Biotech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Trinity Biotech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Trinity Biotech Forecast Models
Trinity Biotech's time-series forecasting models are one of many Trinity Biotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Trinity Biotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Trinity Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Trinity Biotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Trinity shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Trinity Biotech. By using and applying Trinity Stock analysis, traders can create a robust methodology for identifying Trinity entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.58) | (0.56) | |
Operating Profit Margin | (0.43) | (0.41) | |
Net Loss | (0.38) | (0.36) | |
Gross Profit Margin | 0.31 | 0.33 |
Current Trinity Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Trinity analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Trinity analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
7.0 | Strong Buy | 1 | Odds |
Most Trinity analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Trinity stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Trinity Biotech plc, talking to its executives and customers, or listening to Trinity conference calls.
Trinity Stock Analysis Indicators
Trinity Biotech plc stock analysis indicators help investors evaluate how Trinity Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Trinity Biotech shares will generate the highest return on investment. By understating and applying Trinity Biotech stock analysis, traders can identify Trinity Biotech position entry and exit signals to maximize returns.
Begin Period Cash Flow | 6.6 M | |
Long Term Debt | 54.7 M | |
Common Stock Shares Outstanding | 153.1 M | |
Total Stockholder Equity | -23.9 M | |
Tax Provision | -59 K | |
Quarterly Earnings Growth Y O Y | -0.773 | |
Property Plant And Equipment Net | 1.9 M | |
Cash And Short Term Investments | 3.7 M | |
Cash | 3.7 M | |
Accounts Payable | 3.9 M | |
Net Debt | 63.7 M | |
50 Day M A | 0.794 | |
Total Current Liabilities | 15 M | |
Other Operating Expenses | 83.9 M | |
Non Current Assets Total | 20.4 M | |
Non Currrent Assets Other | 43 K | |
Stock Based Compensation | 2.1 M |
Complementary Tools for Trinity Stock analysis
When running Trinity Biotech's price analysis, check to measure Trinity Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trinity Biotech is operating at the current time. Most of Trinity Biotech's value examination focuses on studying past and present price action to predict the probability of Trinity Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trinity Biotech's price. Additionally, you may evaluate how the addition of Trinity Biotech to your portfolios can decrease your overall portfolio volatility.
Stocks Directory Find actively traded stocks across global markets | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |